Most of the current treatments are focusing on anti-apoptotic molecules (Bcl-2) and BCR-signaling kinases (BTK, PI3K), due to the highly stimulated state of CLL cells in the microenvironment. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.